Speaker Profile
Ph.D., Distinguished Scientist, Genentech
Biography
Lélia Delamarre joined the Cancer Immunology Department at Genentech after completing her postdoctoral training at Yale University where she studied the cell biology of antigen presentation in dendritic cells. She obtained a PhD in Virology from Université Pierre et Marie Curie in France. Her laboratory studies the modulation of dendritic cell and T cell functions, with the goal of developing new strategies to enhance immune responses to cancer.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Ira Mellman, Medici Therapeutics
PMWC Award Ceremony
• Jedd D. Wolchok, Weill Cornell Medicine
• Suzanne Topalian, Johns Hopkins
• Levi Garraway, Roche
Targeting the Tumor Microenvironment (TME) in Practice: Biomarkers & Combos
• Chair: Ira Mellman, Medici Therapeutics
• Dmitry Gabrilovich, AstraZeneca
• Shannon Turley, Amgen
Immunotherapy with Personalized Cancer Vaccines: Who, When, How Fast?
• Chair: Suzanne Topalian, Johns Hopkins
• Tal Zaks, Orbimed
• Lelia Delamarre, Genentech
Fireside Chat: Immune Tolerance to Cure
• Mary E. Brunkow, ISB - 2025 Nobel Laureate
• Lee Hood, Phenome Health
ADCs in the Checkpoint Era: Who Benefits, What to Combine, What to Avoid
• Chair: Shreya Badhrinarayanan, Pfizer
• S. Peter Kang, Daiichi Sankyo
• Vadim Koshkin, UC San Francisco
Radiopharmaceutical Therapy: New Targets, Isotopes, and Challenges
• Chair: William Oh, Yale
• Munir Ghesanim, United Theranostics
Strategic IP Management in Cell and Gene Therapy: Navigating Legal and Practical Challenges
• Janet Xiao, Morrison & Foerster LLP
Checkpoint 2.0 in Practice: PD-1+VEGF Wins, Resistance Salvage & Biomarker Gates
• Chair: Anne Kasmar, Parexel
• Jedd D. Wolchok, Weill Cornell Medicine
• Roy S. Herbst, Yale
Future Breakthroughs in Immuno-Oncology: New Targets, Modalities & Combinations
• Chair: Levi Garraway, Roche
